Search results

1. ASCO 2026 preview – Revolution completes its rout

   … vs Tevimbra + chemo LBA4 PFS data were presented at ESMO 2025 Daraxonrasib Pan-RAS inhibitor …

   
    

   Jacob Plieth
    
   - 04/23/2026 - 16:12

2. AACR 2026 – Qilu challenges Torl in Claudin6

   … US ph1 Catalina-1 Venue AACR 2026 ESMO 2025 Cutoff date 21 Jan 2026 28 Jul …

   
    

   Madeleine Armstrong
    
   - 04/21/2026 - 14:06

3. Gilead buys what it tried with Tubulis

   … NaPi2b Ph1/2 Napistar1-01 in PROC & NSCLC; ESMO 2025: 50% ORR among 46 PROC pts TUB-030 ADC …

   
    

   Madeleine Armstrong
    
   - 05/19/2026 - 19:49

4. Kainova bigs up EP4 antagonism

   … Ph1/2 in solid tumours (run by Cancer Research UK) ESMO 2025 data: ORR 0% (0/13) for monotherapy; ORR 9% (2/22) …

   
    

   Jacob Plieth
    
   - 05/19/2026 - 19:49

5. Adjuvant Enhertu gets priority

   … therapy) MonoRx, vs Kadcyla Positive data at ESMO 2025; filed, with 7 July 2026 PDUFA date … + paclitaxel + Herceptin + Perjeta Positive data at ESMO 2025; filed, with 18 May 2026 PDUFA date …

   
    

   Batirtze Areitio
    
   - 05/19/2026 - 19:49

6. Roche flunks its first-line degrader test

   … endocrine therapy Positive data in ESR1m & all-comers at ESMO 2025; FDA filing accepted in ESR1m only; PDUFA date 18 …

   
    

   Madeleine Armstrong
    
   - 05/19/2026 - 19:49

7. Double trouble for Incyte in KRAS

   … Ph1 in KRAS G12Dm solid tumours First data at ESMO 2025; recruitment target 710, but enrolment in Spain, …

   
    

   Jacob Plieth
    
   - 05/19/2026 - 19:49

8. Novartis prunes its pipeline

   … in solid tumours started 2023; disappointing data at ESMO 2025 KFA115 Undisclosed degrader Ph1 …

   
    

   Madeleine Armstrong
    
   - 05/19/2026 - 19:49

9. A first test of OnKure’s mutant-specific gamble

   … plus Faslodex has reported 39% ORR , while tersolisib at ESMO 2025 yielded 18% as monotherapy and 28% as part of a …

   
    

   Jacob Plieth
    
   - 05/19/2026 - 19:49

10. Huabo goes pivotal with bispecific VEGF trap

    … first-line squamous NSCLC Source: Dr Caicun Zhou & ESMO 2025. Data insights …

    
     

    Batirtze Areitio
     
    - 05/19/2026 - 19:49